MAPK1
Mitogen-activated protein kinase 1
As of the edition of 20 October 2026, MAPK1 (mitogen-activated protein kinase 1, UniProt P28482) has 8 drugs tested at it and 9 companies on the list, 7 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P28482
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 160
- Disease areas
- Cancer; Digestive system; Blood and lymph; Hormones; Lungs and airways; Skin and connective tissue; Immune system; Pregnancy and women's health
- Registered trials of its drugs
- 36
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 6 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ulixertinib | Stopped | Phase 2 | none listed |
| Temuterkib | Stopped | Phase 2 | none listed |
| MK-8353 | Stopped | Phase 1 | none listed |
| Ravoxertinib | Went quiet | Phase 1 | none listed |
| ASN007 | Went quiet | Phase 1 | none listed |
| CC-90003 | Stopped | Phase 1 | none listed |
| KO-947 | Stopped | Phase 1 | none listed |
| Tizaterkib | Stopped | Phase 1 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Engaged | 2 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| Merck & Co. | Route A |
| Roche | Route A |
The other 6 companies at MAPK1
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at MAPK1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.